Search research articles
Contact Us
Filters
Showing results (1-10 of 5) with videos related to
Page
of 1
Sort By:
Issue Brief (Center for Studying Health System Change)
|
August 16, 2001
At the brink: how Harvard Pilgrim got in trouble
L R Brewster, P B Ginsburg
Issue Brief (Center for Studying Health System Change)
|
August 1, 2000
Insolvency and challenges of regulating providers that bear risk
L R Brewster, L Jackson, C S Lesser
Issue Brief (Center for Studying Health System Change)
|
October 18, 2001
Emergency room diversions: a symptom of hospitals under stress
L R Brewster, L S Rudell, C S Lesser
Marine Biology
|
March 23, 2018
Development and application of a machine learning algorithm for classification of elasmobranch behaviour from accelerometry data
L R Brewster, J J Dale, T L Guttridge, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 1, 1997
A phase I study of topotecan followed sequentially by doxorubicin in patients with advanced malignancies
A W Tolcher, J A O'Shaughnessy, R B Weiss, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 5) with videos related to
Sort By:
Page
of 1
Issue Brief (Center for Studying Health System Change)
|
August 16, 2001
At the brink: how Harvard Pilgrim got in trouble
L R Brewster, P B Ginsburg
Issue Brief (Center for Studying Health System Change)
|
August 1, 2000
Insolvency and challenges of regulating providers that bear risk
L R Brewster, L Jackson, C S Lesser
Issue Brief (Center for Studying Health System Change)
|
October 18, 2001
Emergency room diversions: a symptom of hospitals under stress
L R Brewster, L S Rudell, C S Lesser
Marine Biology
|
March 23, 2018
Development and application of a machine learning algorithm for classification of elasmobranch behaviour from accelerometry data
L R Brewster, J J Dale, T L Guttridge, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 1, 1997
A phase I study of topotecan followed sequentially by doxorubicin in patients with advanced malignancies
A W Tolcher, J A O'Shaughnessy, R B Weiss, et al.
Page
of 1